Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
Top Cited Papers
- 1 July 2011
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (19), 2709-2716
- https://doi.org/10.1200/jco.2011.35.0371
Abstract
Purpose To evaluate the prognostic value of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) with NPM1 mutation (NPM1mut). Patients and Method RNA-based real-time quantitative polymerase chain reaction (RQ-PCR) specific for the detection of six different NPM1mut types was applied to 1,682 samples (bone marrow, n = 1,272; blood, n = 410) serially obtained from 245 intensively treated younger adult patients who were 16 to 60 years old. Results NPM1mut transcript levels as a continuous variable were significantly associated with prognosis after each treatment cycle. Achievement of RQ-PCR negativity after double induction therapy identified patients with a low cumulative incidence of relapse (CIR; 6.5% after 4 years) compared with RQ-PCR–positive patients (53.0%; P < .001); this translated into significant differences in overall survival (90% v 51%, respectively; P = .001). After completion of therapy, CIR was 15.7% in RQ-PCR–negative patients compared with 66.5% in RQ-PCR–positive...Keywords
This publication has 30 references indexed in Scilit:
- Prognostic Impact of Minimal Residual Disease inCBFB-MYH11–Positive Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- Harmonization of molecular monitoring of CML therapy in EuropeLeukemia, 2009
- Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide TherapyJournal of Clinical Oncology, 2009
- Development of Minimal Residual Disease–Directed Therapy in Acute Myeloid LeukemiaSeminars in Oncology, 2008
- Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early interventionLeukemia, 2007
- Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaBlood, 2006
- Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotypeBlood, 2005
- Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]Leukemia, 2005
- Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal KaryotypeNew England Journal of Medicine, 2005